Home

first-IN-class MEDICATIONs to treat psychostimulant addictions

Through working partnerships with academic institutions, private companies, foundations, and publicly funded government agencies, we create an accelerated pipeline for promising new therapeutics that will fuel the transformation of mental health care.

OUR products

focus on early r&D to create accelerated pathways to fda approval

OUR
approach

We enhance the development of first-in-class medicines to improve treatment of mental health disorders by propelling innovations from the lab into safe, affordable, and effective medicines for our patients.

Our company brings together top researchers and practitioners in the fields of psychiatry, neurology, neuropathology, and neuropharmacology for the efficient development of treatment options to prevent, treat, and cure neurological diseases.